TNXP

Tonix Pharmaceuticals Holding Stock Analysis

AI Rating

Neutral
  • Quality1/10
  • Growth↑ 8/10
  • Momentum↓ 2/10
Tonix Pharmaceuticals Holding sales and earnings growth
TNXP Growth
Good
  • Revenue Y/Y↓ -8.79%
  • EPS Y/Y↑ 109.78%
  • FCF Y/Y↓ -10.32%
Tonix Pharmaceuticals Holding gross and profit margin trends
TNXP Profitability
Low
  • Gross margin ↑ 34.30%
  • EPS margin↓ -963.40%
  • ROIC↓ -210.80%
Tonix Pharmaceuticals Holding net debt vs free cash flow
TNXP Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Tonix Pharmaceuticals Holding stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗